India Chem 2000
October 6-8,2000
THE GLOBAL PHARMACEUTICAL INDUSTRY
SOURCES FROM INDIA ITS
MOST VALUABLE ASSET - BRAIN POWER
IT SHOULD SOURCE WHAT CAN BE
CRATED BY INDIAN BRAIN POWER
Mr. Ian R. Young,
Managing Director,
PFIZER Ltd.
GLOBAL PHARMACEUTICAL MARKET
- $ 340 bn OF WHICH INDIA REPRESENTS 1%
INDIA CAN PROVIDE SERVICES TO THE DISCIPLINES
WHICH GENERATE THE 99% OF THE WORLD MARKET OUTSIDE INDIA.
- PRODUCT COST (MANUFACTURING)
- RESEARCH & DEVELOPMENT
- MARKETING/MEDICAL INFORMATION
- GENERAL ADMINISTRATION
PRODUCT (BULK) SOURCING
| SUPPLIER TO THE
GENERIC INDUSTRY ($20 BILLION P.A) |
REQUIRIES
|
- LARGE VOLUMES
- LOW PRICES
- LIMITED MARGINS
|
LOW COST
ACCEPTABLE QUALITY
|
| SUPPLIER TO THE
RESEARCH BASED INDUSTRY |
- SIGNIFICANT VOLUME
- GOOD PRICES
- HIGHER MARGINS
|
- ACCEPTABLE COST
- 100% QUALITY ASSORANCE
- GUARANTEED PROTECTION OF INTELLECTUAL PROPERTY
RIGHTS
|
RESEARCH & DEVELOPMENT
- $38 bn. p.a.
RESEACH
- SEQUENCING OF THE HUMAN GENOME
- BIO INFORMATICS
- VAST INCREASE IN THE NUMBER OF INDENTIFIED TARGETS
- MANY NICHE DRUGS
- SHORTER LIFE SPAN OF DRUGS
DEVELOPMENT
- MORE NEW DRUG CANDIDATES
- MORE DEVELOPMENT/ CLINICAL TRIALS
- PRESSURE TO REDUCE DRUG DEVELOPMENT COSTS
DEVELOPMENT /CLINICAL TRIALS
BY 2005 - $20bn
ADVANTAGE INDIA
- WELL QUALIFIED DOCTORS AND TECHNICIANS
- SOME WELL EQUIPPED HOSPITALS/INSTITUTIONS
- HUGE PATIENT POPULATION - NOT PREVIOUSLY MEDICATED.
- BIOMETRIC CAPABILITY - COMPUTERIZED TABULATION
AND ANALYSIS
- LOW COST
CLINICAL TRIAL SOURCING
REQUIREMENTS :
- GUARANTEED PROTECTION OF PROPRIETORY KNOWLEDGE/DATA
- TRAINING - QUALITY CONSCIOUSNESS
- REGULATORY CHANGES
- MEDICAL SCHOOLS - CLINICAL PHARMACOLOGY COURSES
- ADOPTION OF ICH GCP GUIDELINES
MARKETING/MEDICAL INFORMATION
- MEDICAL CONFERENCES
- CONFERENCE TRANSCRIPTION SERVICES
- VIDEO/COMPUTER GRAPHIC PRODUCTION ETC
- BACKROOM FUNCTIONS
GLOBAL PHARMACEUTICAL SOURCING
FROM INDIA
THERE MUST BE A GREAT "COMFORT LEVEL"
WITH INDIA
- STONG AND EFFECTIVE PATENTENT LAW
TRAINING AND MOTIVATION
|
